Genetic Mutations
146 articles
New Study Aims to Reduce Recurrence Risk for Select Patients
Dr. Kim A. Reiss is leading a study of the PARP inhibitor olaparib to delay or prevent a recurrence of surgically removed pancreatic cancer.
ASCO Annual Conference: Highlights in Pancreatic Cancer Research
Dr. Allyson Ocean reviews some of the latest pancreatic cancer research results, including new treatments for some patients.
Looking Back at the Year in Research: 2019
Research highlights of 2019 include: approval of a PARP inhibitor, artificial intelligence to diagnose pancreatic cysts, and updated radiation guidelines.
A Registry for Those at Risk for Pancreatic Cancer
Dr. Robert Kurtz founded the Pancreatic Tumor Registry at Memorial Sloan Kettering to learn more about the genetic mutations that cause pancreatic cancer.
Early Detection Trial for People at Higher Risk of Pancreatic Cancer
Relatives of pancreatic cancer patients or people who carry certain mutations can participate in an early detection clinical trial.
Highlights from the 2025 AACR Annual Meeting
Drugs to target KRAS, better imaging for earlier detection, and cachexia prediction are among the research highlights from AACR 2025.
BRCA’s Role in Pancreatic Cancer Investigated
The relationship between BRCA and pancreatic cancer, and how that affects treatment, is the focus of clinical trials looking at PARP inhibitors.
Crafting a Medical Family Tree
Dr. Diane Simeone and genetic counselor Jessica Everett explain why it is important to create a medical family tree for pancreatic cancer.
Precursors to Pancreatic Cancer: Are There Any Signs to Watch Out For?
Dr. Venkata Akshintala outlines some of the precursors to pancreatic cancer that people should look out for.
Pancreatic Cancer Research Builds Upon Strengths
The September 2023 AACR Special Conference on Pancreatic Cancer focused on the latest research in KRAS, chemotherapy, and cachexia, among other topics.
PRECEDE Trial Sets Survival Rate Goal
Dr. Raymond Wadlow explains how earlier detection of high-risk people is key the PRECEDE trial’s goal to increase pancreatic cancer survival rates.
Molecular Profiling: Getting to Know Your Tumor
Dr. Johanna Bendell explains the value of molecular profiling, which can indicate the best type of chemotherapy for your tumor.
Treating BRCA-Negative Pancreatic Cancer Patients with a Family Cancer History Similar to BRCA Carriers
A clinical trial looks at the effectiveness of a PARP inhibitor in BRCA-negative pancreatic cancer patients with a family history BRCA-type cancers.
ASCO GI Symposium Features a Broad Range of Pancreatic Cancer Research
Researchers at ASCO GI 2024 reported on research in health disparities, KRAS and other genetic mutations, and novel treatments.